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license (http://creativelate knowledge on diagnostic tests (magnetic resonance imaging [MRI], cerebrospinal fluid [CSF],
and amyloid positron emission tomography [PET]) to daily clinical practice with a focus on mild
cognitive impairment (MCI)
Methods: ABIDE is a 3-year project with a multifaceted design and is structured into interconnected
substudies using both quantitative and qualitative research methods.
Results: Based on retrospective data, we develop personalized risk estimates for MCI patients. Pro-
spectively, we collect MRI and CSF data from 200 patients from local memory clinics and amyloid
PET from 500 patients in a tertiary setting, to optimize application of these tests in daily practice.
Furthermore, ABIDE will develop strategies for optimal patient-clinician conversations.
Discussion: Ultimately, this will result in a set of practical tools for clinicians to support the choice of
diagnostic tests and facilitate the interpretation and communication of their results.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Dementia; Alzheimer’s disease; Mild cognitive impairment; Biomarkers; Clinical practicethor. Tel.:131 (0)20 444 85 23; Fax:131 (0)20 444
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).1. Introduction
The advent of magnetic resonance imaging (MRI) and
the discovery of cerebrospinal fluid (CSF) biomarkers
and amyloid positron emission tomography (PET) are
among the greatest successes in Alzheimer’s disease
(AD) research, allowing an AD diagnosis in an earlierimer’s Association. This is an open access article under the CC BY-NC-ND
A. de Wilde et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 6 (2017) 143-151144stage of disease [1–5]. Despite a wealth of literature on AD
biomarkers, there is a gap between the published value and
the actual utilization of biomarkers in daily clinical
practice [6,7].
Structural MRI biomarkers incorporated in the National
Institute on Aging and the Alzheimer’s Association diag-
nostic criteria for AD include atrophy, for example, of the
medial temporal lobe, as marker for neurodegeneration [8].
The criteria however lack recommendations for preferred
methods to establish atrophy (quantitatively vs. qualita-
tively), nor do they provide cutoffs [6,7]. CSF biomarkers,
amyloid-beta 1–42 (Ab1–42), total tau (tau), and phosphory-
lated tau (p-tau), discriminate AD patients from persons with
normal aging with high accuracy and predict dementia in pa-
tients with mild cognitive impairment (MCI) [9–11].
However, there is considerable intervariability and
intravariability in the measured levels between the
manually operated CSF platforms, which limits
comparability between centers and establishing cutoff
values [12]. Automated platforms are now being developed,
and this is expected to reduce analytical variability [13]. The
introduction of amyloid PET in 2004 allowed visualization of
amyloid pathology in vivo and the subsequent development
of 18F-labeled tracers enabled widespread implementation
in memory clinics [1,14]. Appropriate use criteria for
amyloid imaging have been published, but at that time,
experience with amyloid PET was limited and based onFig. 1. Patient journey inmemory clinics. (A) Current patient journey inmemory cl
Alzheimer’s biomarkers in daily practice; CSF, cerebrospinal fluid; MRI, magnetdata from highly selected research populations, so it
remains unclear which patients benefit most from costly
amyloid PET imaging in the diagnostic tree [15].
Furthermore, MRI, CSF, and amyloid PET predict pro-
gression fromMCI to dementia, but most available literature
is based on group-level data [16–19]. Translating results to
individual patients in daily practice is difficult, as the
prognostic value of each biomarker may vary with, for
example, age, gender, and cognitive status. Moreover,
when combining biomarkers, interpretation of results
becomes complicated, especially when they are not clearly
positive, negative, or even conflicting. Also, little is known
about patients’ preferences towards diagnostic testing and
best ways of communicating test results with patients and
their caregivers. Such conversations about initiating
diagnostic testing or communicating test results are
challenging for both patients and clinicians. To date, it
remains unknown how these conversations are conducted
in the clinical routine setting, and how patients and
clinicians experience and value these conversations.
The Alzheimer’s biomarkers in daily practice (ABIDE)
project has been designed to address the need for a trans-
lation of the scientific value of AD biomarkers to actual
daily utilization in local memory clinics. Fig. 1 describes
the current patient journey of someone attending a regular
memory clinic and provides an overview of how ABIDE
objectives aim to improve this. ABIDE addresses bothinics. (B) ABIDE patient journey inmemory clinics. Abbreviations: ABIDE,
ic resonance imaging; PET, positron emission tomography.
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how to take patients’ preferences towards testing and
communication of test results into account. Ultimately,
this should lead to a more personalized approach of
the patient in their journey toward a diagnosis in memory
clinics.
Specific objectives include the following: (1) To decide
on themost useful application of specific AD diagnostic tests
in clinical practice (Fig. 1B; displayed in orange), including
(A) comparison of visual rating and volumetric MRI
markers of whole brain atrophy and atrophy of the medial
temporal lobe, (B) comparison of manual and automated
CSF biomarker platforms, and (C) identify patients that
benefit most from amyloid PET. (2) To (A) develop person-
alized risk estimates in MCI patients for (time to) progres-
sion to dementia, and (B) to develop personalized risk
estimates in MCI patients for (time to) progression to de-
mentia (displayed in red). (3) To identify optimal strategies,
tailored to patients’ characteristics, to effectively involve pa-
tients in the decision about diagnostic testing (sharedFig. 2. Hierarchy of ABIDE objectives. Abbreviation: ABIDE, Alzheimer’s biom
imaging; PET, positron emission tomography.decision making) and communicate results of diagnostic
tests (displayed in blue). (4) To develop a tool with algo-
rithms for diagnostic testing and personalized risk estimates,
and to facilitate communication about test results (not dis-
played).2. Methods
2.1. Study design
ABIDE is a 3-year project which has been funded in the
context of the Dutch national dementia plan (https://www.
deltaplandementie.nl/en; project number: 733050201).
ABIDE has a multifaceted design and is structured into five
substudies eachwith their own objective, design, patient sam-
ple, and data collection. Fig. 2 shows the structure of ABIDE
and demonstrates how results from one objective feeds into
the next. In the following, we describe the substudies sepa-
rately. Table 1 provides an overview of the link between ob-
jectives, design, patient samples, and outcome measures.arkers in daily practice; CSF, cerebrospinal fluid; MRI, magnetic resonance
Table 1
ABIDE substudies and corresponding objectives and patient cohorts
Substudy Objective Cohort Data collection
Sample Measures
No. of patients Setting Population MRI CSF PET CON
1 1A, B Prospective Cross-sectional n 5 200 Local Mixed O O
2 1C Prospective Longitudinal n 5 450 Tertiary Mixed O O O
2 1C Prospective Longitudinal n 5 50 Tertiary MCI O O O
3 2A, B Retrospective Longitudinal n 5 400 Tertiary MCI O O
4 3 Prospective Cross-sectional n 5 120 Local Mixed (O) (O) O
Abbreviations: ABIDE, Alzheimer’s biomarkers in daily practice; MRI, magnetic resonance imaging; CSF, cerebrospinal fluid; PET, positron emission to-
mography; CON, memory clinic consultation between clinician and patient and caregiver(s); MCI, mild cognitive impairment.
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(objectives 1A and 1B)2.2.1. Patients and design
In this cross-sectional multicenter study designed to
compare different measurement methods of MRI and CSF
biomarkers, we include 200 patients with subjective cogni-
tive decline (SCD), MCI, or dementia from 10 Dutch local
memory clinics. Clinical assessment is according to local
practice, including at least medical and informant history,
physical examination, and cognitive testing. All patients
who are offered MRI and/or lumbar puncture for diagnostic
purposes are eligible for the study.
2.2.2. Methods—clinical data
We collect basic demographic and clinical information
including age, gender, medical history, use of medication,
clinical diagnosis, Mini-Mental State Examination, neuro-
psychological evaluation, and CDR. We use OpenClinica
open source software, version 3.1 (Copyright  OpenClin-
ica LLC and collaborators, Waltham, MA, USA) for data
management. In addition, we use The Older Persons and
Informal Caregivers Survey Minimal DataSet instrument,
which feeds into a uniformly collected public data reposi-
tory that contains information on the physical and mental
health and well-being of older persons and informal care-
givers across the Netherlands [20].
2.2.3. Methods—MRI
Structural MRI is performed according to local acquisi-
tion protocols and includes at least 3D T1-weighted imaging.
Scans are collected centrally at the VU University Medical
Center (VUmc). After a quality check, we obtain visual
and volumetric measures of medial temporal lobe atrophy,
posterior cortical atrophy, and global cortical atrophy [21–
23]. MRIs will also be visually assessed for white-matter hy-
perintensities, number of infarcts, lacunes and microbleeds
[24].We derive quantitativemeasures of atrophy via the soft-
ware package SIENAX (Structural Image Evaluation using
Normalization of Atrophy Cross-sectional) [25]. The
algorithm FIRST (FMRIBs integrated registration and seg-
mentation tool, FSL 4.15) will be used to estimate volumes
of gray-matter structures including the hippocampus.2.2.4. Methods—CSF
CSF is collected inpolypropylene tubes of10mL(Sarstedt)
after lumbar puncture between L3/L4 or L4/L5 intervertebral
space by a needle and syringe. CSF is centrifuged and then
divided into two new polypropylene tubes (2.5 mL in one,
remainder in other). The tubes are sent to the VUmc Neuro-
chemistry Laboratory, Department of Clinical Chemistry at
the VUmc. CSF is frozen at280C until analysis of the bio-
markers (Ab1–42, tau, and p-tau). CSF samples will be
analyzed using the manually operated Innotest enzyme-
linked immunosorbent assay [26,27]. In addition, we use a
novelRoche automatedplatform,Elecsys immunoassays [28].
2.2.5. Statistics
Wewill compare (1) visual and volumetricMRImeasures
and (2) CSFmeasurements from both platforms using Spear-
man’s rank correlation and concordance measures. For CSF
platform comparison, we will use Passing Bablok regression
analysis. Accuracy, sensitivity, specificity, and negative and
positive predictive value will be compared.
2.3. Sub-study 2—application of amyloid PET (objective 1C)2.3.1. Patients and design
In this prospective observational study, we offer amyloid
PET to all patients visiting our tertiary referral center during
1 year (n 5 450) to assess its diagnostic value in an unse-
lected sample of memory clinic patients. Standard diag-
nostic workup at the memory clinic of the VUmc
Alzheimer Center includes medical history, neurological ex-
amination, neuropsychological evaluation, basic laboratory
testing, and MRI [29]. Additionally, we enroll 50 MCI pa-
tients with similar diagnostic workup from the University
Medical Center Utrecht (UMCU) to enrich the cohort for
MCI. We will follow all patients for one year, to verify diag-
nosis (dementia) or to assess clinical progression (SCD and
MCI). Primary outcome measures are change in diagnosis,
change in confidence in diagnosis, and change in planned pa-
tient management following amyloid PET results.
2.3.2. Methods
At the VUmc, amyloid PET scans are made with 3-Tesla
Philips Ingenuity TF PET/MR, Philips Ingenuity TF
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uses a Siemens Biograph 40 MCT scanner. Before and after
scanning, patients fill out a questionnaire regarding their ex-
pectations and perceptions of amyloid PET. Patients are in-
jected with a tracer dose of approximately 300 MBq6 20%
18F-florbetaben (NeuraceqTM). The image acquisition win-
dow extends from 90 to 110 minutes (4! 5-minute frames)
after dose injection. PET scans are collected centrally at the
VUmc and visually assessed by an experienced nuclear
physician (B.V.B.) for amyloid positivity (yes/no).
For each patient, a preamyloid and postamyloid PET
diagnosis is obtained with a level of confidence indicated
by the neurologist (F.B. at the VUmc and G.J.B. at the
UMCU) varying from 0%–100%. Also, the neurologists
are asked about patient management before and after amy-
loid PET scan results are revealed, to assess a change in
ancillary investigations, care, and medication.
2.3.3. Statistics
We will assess change of syndrome diagnosis and sus-
pected underlying pathophysiology. To assess differences
in change of diagnostic confidence among diagnostic
groups, we will use analysis of variance for repeated mea-
sures with group as between-subjects variable and (change
in) diagnostic confidence as within-subjects variable.
Finally, we will evaluate whether the appropriate use criteria
for amyloid imaging select those patients that are affected
most by amyloid PET, in terms of change in diagnosis and
change of planned management.2.4. Substudy 3—algorithms for diagnostic testing and
personalized risk estimates (objectives 2A and 2B)2.4.1. Patients and design
In this retrospective, longitudinal study designed to
develop individualized risk estimates, we include MCI pa-
tients with baseline MRI and/or CSF and at least one year
of clinical follow-up from the Amsterdam Dementia Cohort
[29]. Clinical diagnoses of MCI were made in a multidisci-
plinary team according to international guidelines [6,31].
Progression to AD dementia at clinical follow-up is the
outcome measure [8].
2.4.2. Methods—personalized risk estimates
Wewill use Cox proportional hazards analyses to develop
prognostic models for MRI biomarkers (ordinal), for CSF
biomarkers (continuous), and for the two combined. To ac-
count for patient diversity, we will explicitly take gender,
age, and MMSE into account [32,33]. The resulting
models will allow to derive individual risk estimates and
95% confidence intervals for a patient with any given age,
gender, MMSE, and biomarkers result (MRI and/or CSF).
In addition, we will obtain estimates of probability ofprogression, within 1 year and within 3 years, facilitating
translation of these risk scores to the clinical setting.
Five-fold cross-validated Harrell’s concordance index will
be used to validate the models.
2.4.3. Methods—algorithms for diagnostic testing
To develop algorithms for selection of diagnostic tests,
that is, MRI and CSF, wewill perform an extensive literature
search on the diagnostic and prognostic value of individual
and combined tests, taking special care to account for patient
diversity [34]. We will combine the literature search results
with the retrospective cohort data to develop algorithms
for selection of tests. Subsequently, we will validate these
rules in the prospective sample of local memory clinics
(see objective 1).2.5. Substudy 4—identifying optimal strategies for shared
decision making and communication of test results
(objective 3)2.5.1. Patients, design, and methods
Wewill use qualitative and quantitative research methods
to study shared decision making and patient–clinician
communication. First, to identify which diagnostic di-
lemmas occur in the consultation room, we will organize
separate focus groups for clinicians, patients, and caregivers
(n5 10 per focus group). Participants will be asked to share
their views, experiences, and perceived dilemmas regarding
diagnostic testing and communication of test results. Focus
group discussions will be audiotaped, transcribed, and coded
using MAXQDA software [30].
Second, we will perform an observational audiotaping
study in the routine diagnostic workup of dementia. We
will assess patient–clinician communication in both prediag-
nostic and postdiagnostic testing consultations in 12 mem-
ory clinics (n 5 10 per clinician, n 5 240 consultations in
total). After each consultation, patients and their caregivers
will receive a brief questionnaire on their views and experi-
ences. Based on insights gained from the consultations and
focus groups, we will extract a set of recommendations on
how to effectively involve patients and caregivers in
deciding about diagnostic testing, and on how to best discuss
the results of such diagnostic tests.2.6. Substudy 5—practical e-based tools and
implementation (objective 4)
Ultimately, to facilitate communication about diagnostic
tests in the daily routine of memory clinics, we aim to
develop tools that can be used by clinicians in daily practice.
We will combine our results from the best application of
MRI, CSF, and amyloid PET biomarkers (objective 1)
with the developed algorithms for diagnostic testing,
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tions for patient–clinician communication (objective 3) to
create practical tools that can be used in the care process
(Fig. 2).
To prepare for the implementation and test phase of these
tools, we will develop training sessions for clinicians. We
will prospectively pilot and validate the tools in the panel
of participating local memory clinics. To provide an infra-
structure for nationwide implementation of ABIDE results
in the Netherlands, we recently established the Dutch Mem-
ory Clinic Network. This network aims to provide a platform
for clinicians working at the more than 90 memory clinics in
the Netherlands, enabling them to share new knowledge,
harmonize diagnostic and treatment protocols, and facilitate
participation in research.3. Expected results
ABIDE officially started on December 1, 2014 and is a
4-year project (end date: November 30, 2018). In the first
year, we obtained institutional review board approval for
the different substudies. Subsequently, we started with the
inclusion of patients for the different substudies (Table 1).
To date, at the end of the second project year, inclusion tar-
gets for substudies 1, 2, and 3 have largely been reached. In
substudy 1, we collected n5 202 patients with MRI (target:
n5 200) and n5 135 with CSF (target: n5 200) from local
memory clinics. In substudy 2, we collected n 5 495 mem-
ory clinic patients with amyloid PET (target: n5 450 mixed
memory clinic 1 n 5 50 MCI). The retrospective data
collected from the Amsterdam Dementia Cohort for sub-
study 3 includes n 5 525 MCI patients (mean age 67 [68]
years; 60% males; mean MMSE 27 [62]; mean follow-up
duration 2.4 [61.6] years). Finally, for substudy 4, we held
focus groups to identify and discuss diagnostic dilemmas
with professionals, patients, and caregivers and conducted
an online survey among almost 100 memory clinic profes-
sionals. We are currently conducting the audiotape study
and have included n5 65 of prediagnostic and postdiagnos-
tic audiotaped consultations from local memory clinics
(target n5 120). Data lock for substudies 1 and 2 is expected
in Q1 of 2017 and for substudy 4 in Q3 2017.
In the third project year, we will finish data collection,
perform statistical analyses, create a prototype of the prac-
tical e-based tool (substudy 5), and publish first results.
The fourth and final year will consist of finalizing data ana-
lyses, publishing results, and pilot and validate the practical
e-based tool in local memory clinics.
An important milestone was the launch of the Dutch
Memory Clinics Network (Nederlands Geheugenpoli Net-
werk [NGN]; www.geheugenpoliklinieken.nl), linking the
more than 90 memory clinics in the Netherlands. This
network will facilitate the exchange of knowledge and re-
sources, harmonize diagnostic and treatment protocols,
and facilitate participation in research. In addition, we will
use this network for dissemination of ABIDE results.4. Discussion
The major research advances in AD biomarkers (MRI,
CSF, and amyloid PET) have led to earlier and more accurate
diagnoses, but these developments come with new chal-
lenges. First, the availability of biomarker tests poses the
clinician for the challenge to select the right tests for each
patient. Second, effectively communicating with patients
and deciding mutually whether to use certain tests is diffi-
cult, especially in view of the cognitive deficits that come
with (prodromal) AD. Third, biomarker results could affect
(future) choices made by patients and their caregivers, espe-
cially when it concerns nondemented patients. With the
advent of AD biomarkers, their disclosure to nondemented
patients in clinical practice is therefore an emerging topic
in research. Fourth, from an economic perspective, bio-
markers should only be applied if the results are useful, for
example, when changing patient management or preventing
crises later in the disease process. The ABIDE study aims to
address the practical use of AD biomarkers by the clinician
and how to take patients’ preferences toward testing and
communication of test results into account.
In contrast to amyloid PET, MRI and CSF biomarkers are
already widely used in clinical practice. Nonetheless, even
for these tests, a lot of work still needs to be done to translate
research findings to daily practice as clinicians vary greatly
in their knowledge of these markers. In this context of clin-
ical use of AD biomarkers, ABIDE is aligned with several
ongoing research initiatives. For example, the Geneva Task
Force for the Roadmap of Alzheimer’s biomarkers works
on a plan of actions that are needed to accelerate the imple-
mentation of AD biomarkers in daily practice [35,36].
ABIDE adds to this study by prospectively evaluating the
use of MRI and CSF in local memory clinics. When it
comes to amyloid PET, its use is self-evident with respect
to clinical trials in AD (e.g., generation [NCT02565511],
early [NCT02569398], and A4 [NCT02008357]), but clin-
ical utility still has to be established [37,38]. Currently, the
Imaging Dementia–Evidence for Amyloid Scanning study
(www.ideas-study.org) in the United States and the
Amyloid Imaging to Prevent Alzheimer’s Disease study
(http://www.amypad.eu) in Europe assess the clinical
utility of amyloid PET in the diagnostic workup of AD.
ABIDE adds to these initiatives by including an unselected
memory clinic cohort. This will allow us to empirically
evaluate the appropriate use criteria for amyloid imaging.
The decision for clinicians whether to initiate diagnostic
testing and choosing a test is still quite novel, so it is not yet
common practice to involve patients and their caregivers in
their diagnostic dilemmas. ABIDE will provide insight in
the degree of shared decision making during the diagnostic
dementia workup and will help identify roadblocks for the
involvement of patients and their caregivers. By translating
this knowledge into recommendations for best practice, we
can facilitate patients and clinicians to engage in a conversa-
tion and work together in choosing care that fits the
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personalized care and management strategies.
In the context of preclinical AD trials, somework has been
done on risk disclosure to nondemented individuals, based on
APOE genotype and/or amyloid status [39–42]. Also, the
European Prevention of Alzheimer’s Dementia will address
ethical aspects of risk disclosure [43]. However, none of
these studies focuses on disclosure of test results to nonde-
mented patients in the clinical setting. ABIDE adds to these
ongoing initiatives, as we focus on diagnostic dilemma’s in
daily clinical routine and will deliver practical support to
facilitate communication of test results in the clinical setting.
The worldwide costs of dementia care keep rising, and
treatments that prevent or delay AD are not yet available so
far [44]. Diagnosing patients in an early stage of disease is
important instrument to manage the impact of dementia but
also comes with costs [45]. Early diagnosis might reduce
costs later on in the disease process, as a well-informed pa-
tient is less likely to experience crisis situations or prema-
ture institutionalization. ABIDE attempts to harmonize and
improve the diagnostic workup with the ultimate goal of
patient-centered diagnostic care, based on current scientific
knowledge, clinician expertise, and patient preferences.
Evaluation whether such strategies are cost-efficient will
be a necessary next step [46].
ABIDE attempts to take the next step in the dementia
workup by considering what specific test results imply for
individual patients. We will incorporate the developed indi-
vidualized risk models in practical tools, which will facili-
tate the use of these diagnostic tests by clinicians in daily
practice. By involving the main stakeholders of these novel
diagnostic tests, that is, patients, caregivers, and profes-
sionals working in local memory clinics, ABIDE attempts
to truly translate findings from research to the clinic, with
the ultimate goal to improve the quality of diagnostic care.Acknowledgments
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1. Systematic review:We searchedPubMed for literature
on diagnostic value and practical use of Alzheimer’s
disease (AD) biomarkers and guidelines. We
concluded that guidelines on which test to use, in
which setting, for which patient and how to weigh
and communicate biomarker results to patients are
lacking.
2. Interpretation: Alzheimer’s biomarkers in daily prac-
tice (ABIDE) has been designed to address the need
for a translation of the scientific value of AD bio-
markers to actual daily utilization by local memory
clinic physicians. ABIDE is aligned with several
ongoing research initiatives (Imaging Dementia–Ev-
idence for Amyloid Scanning, Amyloid Imaging to
Prevent Alzheimer’s Disease, Geneva Task Force
for the Roadmap of Alzheimer’s Biomarkers, Euro-
pean Prevention of Alzheimer’s Dementia) in that it
studies clinical utility of AD biomarkers. ABIDE
takes the next step in the dementia diagnostic workup
by considering what specific test results imply for in-
dividual patients.
3. Future directions: ABIDE attempts to develop
patient-centered diagnostic care. To achieve this,
we will develop e-based tools to support the diag-
nostic process.
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